Answers are grounded in this paper and cite their sources.
Palmoplantar psoriasis (PP) is a particular type of psoriasis that can justify systemic treatment. Roflumilast is a targeted inhibitor of phosphodiesterase-4 that has been recently approved by the US Food and Drugs Administration as a cream for the treatment of plaque psoriasis. In a small randomized clinical trial and single case reports, oral roflumilast has demonstrated efficacy in the treatment of plaque psoriasis. To the best of our knowledge, we present the first case series of patients with PP treated with oral roflumilast.
No takes yet. Share an insight, caveat, or question.
Lasheras‐Pérez et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: